Buzzard Pharmaceuticals AB is based at the Karolinska Institute Science Park in Stockholm and was founded in 2016 by Urban Paulsson and Maarten de Château. The company has acquired the rights to isunakinra from Eleven Biotherapeutics in 2017 with the intent to re-position isunakinra in cancer indications. Isunakinra is a chimeric protein binding to IL1R1 and inhibiting IL-1 signaling with high potency.
- Bli medlem
- Om SwedenBIO